KAT8: A Promising Biomarker for the Prognosis of Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
Journal of Gastroenterology and Hepatology · 2026-04 · 41 (4) · 1244-1253
DOI: 10.1111/jgh.70313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 06.03.2026. Verfasst von Xiaolin Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Fourth Department of Liver Disease, Beijing Key Laboratory of Liver Regeneration and Artificial Liver Transformation Research, Beijing Youan Hospital…. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Hepatitis B, Chronic, Histone Acetyltransferases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Beijing Hospitals Authority's Ascent Plan, Capital's Funds for the Health Improvement and Research.
Abstract (Originalsprache)
Background and Aims Patients with hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF) have a high short‐term mortality. This study aims to explore the predictive value of KAT8 in ACLF.
Methods
In this study, a carbon tetrachloride/lipopolysaccharide/D‐galactosamine‐induced ACLF mouse model was established. In parallel, PBMCs were collected from a prospective cohort comprising patients with HBV‐ACLF, chronic hepatitis B (CHB), HBV‐related liver cirrhosis (LC), and healthy individuals (HI) to investigate the association between KAT8 expression and ACLF.
Results
In liver tissues from the ACLF animal model, the expression of KAT8 was significantly decreased. Meanwhile, in human PBMCs, KAT8 expression levels were significantly lower in the HBV‐ACLF group than in HI, but higher than those in patients with CHB and HBV‐related LC. Furthermore, survivors exhibited significantly higher KAT8 levels than non‐survivors (all p < 0.001). KAT8 shows potential prognostic value for 28‐day and 90‐day mortality in HBV‐ACLF, with AUROC values of 0.90 and 0.97, respectively.
Conclusions
KAT8 may serve as a valuable biomarker for the prognosis prediction of patients with HBV‐ACLF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fourth Department of Liver Disease, Beijing Key Laboratory of Liver Regeneration and Artificial Liver Transformation Research, Beijing Youan Hospital, Capital Medical University, Beijing, China.
- Department of Gastroenterology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Wenling Wang, Yu Chen
Förderung
- Beijing Hospitals Authority's Ascent Plan
- Capital's Funds for the Health Improvement and Research
Zitieren
APA
Wang, X., Wang, W., Huang, L., Yang, Y., Lu, W., Wu, Y., Xu, M., & Chen, Y. (2026). KAT8: A Promising Biomarker for the Prognosis of Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure. Journal of Gastroenterology and Hepatology, 41(4), 1244-1253. https://doi.org/10.1111/jgh.70313
Vancouver
Wang X, Wang W, Huang L, Yang Y, Lu W, Wu Y, et al. KAT8: A Promising Biomarker for the Prognosis of Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure. Journal of Gastroenterology and Hepatology. 2026;41(4):1244-1253. doi:10.1111/jgh.70313
BibTeX
@article{Wang2026,
author = {Wang, Xiaolin and Wang, Wenling and Huang, Long and Yang, Yanrong and Lu, Wang and Wu, Yu and Xu, Manman and Chen, Yu},
title = {KAT8: A Promising Biomarker for the Prognosis of Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {4},
pages = {1244--1253},
doi = {10.1111/jgh.70313}
}
EUVIMED